Looking ahead to 2019, it appears that many of the health care issues that rose to prominence in 2018 will continue to be front and center. The Trump administration is pressing ahead with the US Department of Health & Human Services blueprint to lower drug prices and reduce out-of-pocket costs, and both the newly elected and re-elected members of Congress have pledged to keep up the pressure on health care spending, with a particular focus on biopharmaceuticals. The actions taken during the next few months could affect the future of the American health care system in both the short and long term.
In his latest column in Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard explains that rather than trying to score news headlines, what we need is a thoughtful, research-based approach to tackle the challenges ahead of us. Looking through the lens of NPC’s research and collaborative activities, Mr. Leonard outlines how we can address the issues raised in the administration’s blueprint and move toward a more value-based health care system.